As small molecule inhibitors targeting CREB are being developed (Mitton et al, 2016), the involvement of CREB in FLT3/ITD pathogenesis as demonstrated in this study may provide new opportunities for therapeutic combination with FLT3 inhibitors in FLT3/ITD AML. This evidence concerns the gene CREB1 and acute myeloid leukemia.